These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 6159908)

  • 1. [Clinical significance of pyridoxine administration in L-dopa therapy of Parkinsonism (author's transl)].
    Namba S; Ishimitsu H; Nakasone S
    No To Shinkei; 1980 Oct; 32(10):991-1000. PubMed ID: 6159908
    [No Abstract]   [Full Text] [Related]  

  • 2. [Effects of simultaneous administration of pyridoxine in the combined administration of L-dopa and peripheral decarboxylase inhibitors. Experimental and clinical studies].
    Namba S; Omoto T; Kishikawa H
    No To Shinkei; 1976 Aug; 28(8):815-22. PubMed ID: 829033
    [No Abstract]   [Full Text] [Related]  

  • 3. [Combined therapy of parkinsonism with bromocriptine, L-dopa and decarboxylase inhibitor (author's transl)].
    Vardy J; Rabey JM; Streifler M
    Harefuah; 1977 Sep; 93(5-6):129-33. PubMed ID: 924233
    [No Abstract]   [Full Text] [Related]  

  • 4. [CB 154 in the treatment of parkinson's disease--results of the association with L-DOPA + DDI (author's transl)].
    Meco G; Casacchia M; Zamponi A; Agnoli A
    Schweiz Rundsch Med Prax; 1976 May; 65(18):557-9. PubMed ID: 989900
    [No Abstract]   [Full Text] [Related]  

  • 5. Treating parkinsonism with L-dopa and carboxylase inhibitor.
    Shau-Fong K; Ho YM
    Mod Med Asia; 1977 Sep; 13(9):23-5. PubMed ID: 600260
    [No Abstract]   [Full Text] [Related]  

  • 6. [Long-term study on the anti-rigidity effect of L-dopa and a decarboxylase inhibitor (ro 8-0576) (author's transl)].
    Eisenlohr JJ; Gehlen W
    MMW Munch Med Wochenschr; 1974 Jul; 116(28):1353-6. PubMed ID: 4212699
    [No Abstract]   [Full Text] [Related]  

  • 7. Dopaminergic agonist effects on Parkinsonian clinical features and brain monamine metabolism.
    Rinne UK; Sonninen V; Marttila R
    Adv Neurol; 1975; 9():383-92. PubMed ID: 1096575
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Improved therapeutic response to L-dopa in Parkinson's disease, when combined with bromocriptine (author's transl)].
    Ulm G
    Nervenarzt; 1981 Feb; 52(2):116-20. PubMed ID: 7219619
    [No Abstract]   [Full Text] [Related]  

  • 9. "Long term evaluation of combined treatment of Parkinson disease with L-dopa, peripheral decarboxylase inhibitors and bromocreptine".
    Caraceni T; Giovannini P; Girotti F; Parati E; Pederzoli M; Scigliano G
    Ital J Neurol Sci; 1981 Dec; 2(4):337-42. PubMed ID: 7333824
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DL-threo-3,4-dihydroxyphenylserine for freezing symptom in parkinsonism.
    Narabayashi H; Kondo T; Nagatsu T; Hayashi A; Suzuki T
    Adv Neurol; 1984; 40():497-502. PubMed ID: 6421112
    [No Abstract]   [Full Text] [Related]  

  • 11. [Combined treatment of parkinsonism with L-dopa and Parkopan].
    Lukasiewicz K
    Wiad Lek; 1977 May; 30(10):775-7. PubMed ID: 867994
    [No Abstract]   [Full Text] [Related]  

  • 12. The effect of R-(-)-deprenyl in de novo parkinsonian patients pretreated with levodopa and decarboxylase inhibitor correlated to depression and MHPS, HIAA, and HVA levels of cerebrospinal fluid.
    Przuntek H; Kuhn W
    Adv Neurol; 1990; 53():445-9. PubMed ID: 1700583
    [No Abstract]   [Full Text] [Related]  

  • 13. [L-dopa treatment in parkinsonism. Biochemical basis (author's transl)].
    Bieniowa A; Kolasa M; Reichowa J
    Przegl Lek; 1976; 33(4):463-7. PubMed ID: 1273343
    [No Abstract]   [Full Text] [Related]  

  • 14. [Combined administration of cholinolytic metamizil and L-Dopa in vascular parkinsonism].
    Kamenetskiĭ VK
    Klin Med (Mosk); 1978 Sep; 56(9):113-5. PubMed ID: 703225
    [No Abstract]   [Full Text] [Related]  

  • 15. Report on 45-month treatment of parkinsonism with L-dopa, alone and in association with a decarboxilase inhibitor (Ro 4-4602).
    Chouza C; Romero S; Gomensoro JB
    Acta Neurol Latinoam; 1974; 20(1-4):116-38. PubMed ID: 4619960
    [No Abstract]   [Full Text] [Related]  

  • 16. [The additive effect of amantadine hydrochloride (Symmetrel) on parkinsonian patients receiving levodopa treatment (author's transl)].
    Shiozawa R; Kase M; Kuroiwa Y; Narabayashi H; Nishitani Y; Ohmoto T; Toyokura Y; Uono K
    No To Shinkei; 1981 Mar; 33(3):301-9. PubMed ID: 7018522
    [No Abstract]   [Full Text] [Related]  

  • 17. [Results of prolonged treatment of Parkinson's disease with the L-dopa-benserazide combination].
    Casacchia M; Barba C; Ruggieri S; Zamponi A; Agnoli A
    Riv Neurol; 1974; 44(5):303-30. PubMed ID: 4217465
    [No Abstract]   [Full Text] [Related]  

  • 18. Dopaminergic supersensitivity in parkinsonism.
    Birkmayer W; Danielczyk W; Neumayer E; Riederer P
    Adv Neurol; 1975; 9():121-9. PubMed ID: 1146650
    [No Abstract]   [Full Text] [Related]  

  • 19. [Effects of additional medication of Amantadine sulfate in L-dopa-pretreated patients with Parkinson's syndrome (author's transl)].
    Schneider E; Fischer PA; Jacobi P
    Med Klin; 1974 Mar; 69(13):541-5. PubMed ID: 4831456
    [No Abstract]   [Full Text] [Related]  

  • 20. [Absorption, excretion, and clinical effects of L-dopa preparation with superenteric coating in parkinsonism (author's transl)].
    Tohgi H; Ogawa M
    No To Shinkei; 1977 Aug; 29(8):873-8. PubMed ID: 907761
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.